| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11018174 | Urologic Oncology: Seminars and Original Investigations | 2018 | 11 Pages |
Abstract
Patients diagnosed with mRCC in the targeted therapy era have improved overall survival when treated at high mRCC-volume facilities, suggesting a volume-outcome association in medical oncology-managed metastatic solid tumors.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Yu-Wei M.D., M.S., Moshe C. M.D. M.A., Laura S. M.S.N., Kimberly D. C.N.P., Allison P.A.-C., Jennifer R.N., Timothy M.D., Jorge A. M.D., Brian I. M.D.,